Last reviewed · How we verify
009-A1
At a glance
| Generic name | 009-A1 |
|---|---|
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease (PHASE1)
- Staccato Apomorphine Single and Multi Dose PK (PHASE1)
- A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |